NewAmsterdam Pharma reported third quarter 2026 revenue of US$19.16 million and a net loss of US$17.39 million, with basic and diluted loss per share from continuing operations of US$0.14. The firm’s ...
Source LinkNewAmsterdam Pharma reported third quarter 2026 revenue of US$19.16 million and a net loss of US$17.39 million, with basic and diluted loss per share from continuing operations of US$0.14. The firm’s ...
Source Link
Comments